Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[4] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.[5]
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[6] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[6]
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[7]